Rekah Pharmaceutical Industry Valuation

Q: What is the Fair Price of REKA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

REKA (₪14.22) is trading above our estimate of [[fair value]] (₪12.13)

Is REKA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REKA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REKA (₪14.22) is trading above our estimate of fair value (₪12.13)

Significantly Below Fair Value: REKA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REKA?

Key metric: As REKA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for REKA. This is calculated by dividing REKA's market cap by their current earnings.
What is REKA's PE Ratio?
PE Ratio	23.8x
Earnings	₪6.81m
Market Cap	₪162.32m

REKA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.9x
Enterprise Value/EBITDA	6.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does REKA's PE Ratio compare to its peers?

The above table shows the PE ratio for REKA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20.2x
GFC-M G.F.C Green Fields Capital	5.4x	n/a	₪115.4m
4102 Yung Zip Chemical Ind	15.7x	n/a	NT$1.4b
A000220 Yuyu Pharma	39.4x	n/a	₩68.0b
A044960 Eagle Veterinary TechnologyLtd	20.4x	n/a	₩60.5b
REKA Rekah Pharmaceutical Industry	23.8x	n/a	₪162.3m

Price-To-Earnings vs Peers: REKA is expensive based on its Price-To-Earnings Ratio (23.8x) compared to the peer average (20.2x).

Price to Earnings Ratio vs Industry

How does REKA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

12 Companies	Price / Earnings	Estimated Growth	Market Cap

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: REKA is good value based on its Price-To-Earnings Ratio (23.8x) compared to the Asian Pharmaceuticals industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is REKA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REKA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	23.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate REKA's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Evogene

₪32.5m

Operates as a computational biology company.

EVGN

₪6.07

-10.8%

-72.3%

Protalix BioTherapeutics

US$112.5m

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

PLX

US$7.33

-0.1%

97.5%